CAS NO: | 1235032-75-3 |
生物活性 | Bcl-xL antagonist2 is a potent, selective, and orally active antagonist ofBCL-XLwith anIC50andKiof 0.091 μM and 65 nM, respectively.Bcl-xL antagonist2 promotes theapoptosisofcancercells.Bcl-xL antagonist2 has the potential for the research of the chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL)[1][2]. | ||||||||||||||||
IC50& Target | 0.091 μM (BCL-XL)[1] | ||||||||||||||||
体内研究 (In Vivo) | Assessment of Pharmacokinetics (PK) profile of Bcl-xL antagonist 2 (compound 14) in rat[1].
| ||||||||||||||||
分子量 | 436.51 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C21H16N4O3S2 | ||||||||||||||||
CAS 号 | 1235032-75-3 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 62.5 mg/mL(143.18 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
*以上所有助溶剂都可在本网站选购。 |
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024 |